Back to Search Start Over

Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection

Authors :
Miriam Merad
B. Escudier
T. Tursz
Fabrice Andre
Gosse J. Adema
Noël E. C. Schartz
Jacky Bernard
Eric Angevin
Antoine F. Carpentier
Julien Taieb
Laurence Zitvogel
Malcolm Adams
Nathalie Aubert
Nathalie Chaput
Sophie Novault
Pierre Bonnaventure
François A. Lemonnier
Maria Ferrantini
Source :
Scopus-Elsevier, Journal of Immunology, 172, 4, pp. 2137-46, Journal of Immunology, 172, 2137-46
Publication Year :
2004
Publisher :
The American Association of Immunologists, 2004.

Abstract

Contains fulltext : 58490.pdf (Publisher’s version ) (Closed access) Ideal vaccines should be stable, safe, molecularly defined, and out-of-shelf reagents efficient at triggering effector and memory Ag-specific T cell-based immune responses. Dendritic cell-derived exosomes could be considered as novel peptide-based vaccines because exosomes harbor a discrete set of proteins, bear functional MHC class I and II molecules that can be loaded with synthetic peptides of choice, and are stable reagents that were safely used in pioneering phase I studies. However, we showed in part I that exosomes are efficient to promote primary MHC class I-restricted effector CD8(+) T cell responses only when transferred onto mature DC in vivo. In this work, we bring evidence that among the clinically available reagents, Toll-like receptor 3 and 9 ligands are elective adjuvants capable of triggering efficient MHC-restricted CD8(+) T cell responses when combined to exosomes. Exosome immunogenicity across species allowed to verify the efficacy of good manufactory procedures-manufactured human exosomes admixed with CpG oligonucleotides in prophylactic and therapeutic settings of melanoma in HLA-A2 transgenic mice. CpG adjuvants appear to be ideal adjuvants for exosome-based cancer vaccines.

Details

ISSN :
15506606 and 00221767
Volume :
172
Database :
OpenAIRE
Journal :
The Journal of Immunology
Accession number :
edsair.doi.dedup.....464efdbe3c1432c20bb3bacd58075fd0